Patent ID: 8481485

Claim:
A high potency insulin analog comprising an A chain sequence of GIVEQCCX 1 SICSLYQLENX 2 CX 3 (SEQ ID NO: 3): and a B chain sequence of X 11 VNQX 4 LCGX 5 X 6 LVEALYLVCGERGFFYTX 9 X 10 (SEQ ID NO: 5), wherein X 1 is selected from the group consisting of threonine and histidine; X 2 is an amino acid of the general structure wherein R 4 is NH 2 or OCH 3 ; and X 3 is asparagine, glycine or alanine; X 4 is selected from the group consisting of histidine and threonine; X 5 is selected from the group consisting of alanine, glycine and serine; X 6 is selected from the group consisting of histidine, aspartic acid, glutamic acid, homocysteic acid and cysteic acid; X 9 is aspartate-lysine dipeptide, a lysine-proline dipeptide, or a proline-lysine dipeptide; X 10 is threonine, alanine, or a threonine-arginine-arginine tripeptide; X 11 is selected from the group consisting of phenylalanine and desamino-phenylalanine or an analog thereof comprising a sequence that differs from SEQ ID NO: 3 and/or SEQ ID NO: 5 by 1 to 5 amino acid modifications, selected from amino acid substitutions at positions A5, A8, A9, A10, A14, A15, A17, A18, B1, B2, B3, B4, B5, B13, B14, B17, B20, B22, B23, B26, B27, B28, B29 and B30, or by the deletion of amino acids B1-4 and/or B26-30 wherein the insulin analog exhibits at least 70% activity at the insulin receptor relative to native insulin.